Gary L Olson, Ph.D

1971-1998 Chemistry Hoffmann-La Roche 
 1998-2001 Praecis Pharmaceuticals Inc. 
 2001- Provid Pharmaceuticals Inc. 
"Gary Olson"
Mean distance: (not calculated yet)


Sign in to add mentor
Gilbert Stork research assistant 1964-1967 Columbia
William Summer Johnson grad student 1967-1971 Stanford
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Huynh M, Eggenhuizen PJ, Olson GL, et al. (2019) HLA-DR15-specific inhibition attenuates autoreactivity to the Goodpasture antigen. Journal of Autoimmunity
Ji N, Somanaboeina A, Dixit A, et al. (2013) Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis. Journal of Immunology (Baltimore, Md. : 1950). 191: 5074-84
Burns-Hamuro LL, Ma Y, Kammerer S, et al. (2003) Designing isoform-specific peptide disruptors of protein kinase A localization. Proceedings of the National Academy of Sciences of the United States of America. 100: 4072-7
Sarabu R, Bolin DR, Campbell R, et al. (2002) Oxazole- and imidazole-based Ser-Leu dipeptide mimetics in potent inhibitors of antigen presentation by MHC class II DR molecules. Drug Design and Discovery. 18: 3-7
Bolin DR, Swain AL, Sarabu R, et al. (2000) Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. Journal of Medicinal Chemistry. 43: 2135-48
Falcioni F, Ito K, Vidovic D, et al. (1999) Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules. Nature Biotechnology. 17: 562-7
See more...